DATAR - CrystalMC

DATAR - CANCER DIAGNOSIS

Personalised medicine focuses on tailoring the treatment strategy to the individual patient.
It is therefore necessary to analyse the specific characteristics and features of the tumour in order to determine the best possible therapy.
In addition, some of this information can also be used for early tumour detection or to perform tumour screening in asymptomatic individuals.

Datar Cancer Genetics has set itself the task of offering solutions, especially for advanced stages (e.g. breast cancer, prostate cancer) or for solid tumours that are difficult to treat. At the same time, we recognise that early detection of cancer is much more likely to lead to successful treatment, for example in colon cancer or ovarian carcinoma. There is a wealth of information available in the blood, the analysis of which, combined with advanced artificial intelligence, helps to optimise therapy. Based on clinical studies in recent years, Datar Cancer Genetics has been able to develop evidence-based testing procedures in both therapy management and cancer screening. In total, more than 40,000 patients have been enrolled in our studies to date, making a significant contribution to cancer diagnosis and therapy.

Minimally invasive

Quick results

Early detection of cancer/tumour

Identification of a relavant target for individual therapy

Monitoring tumour development

Trucheck™ is a new blood paradigm for the detection of multiple cancers.

The following options are available:

– Trucheck™ intelli (up to 70 types of solid tumours)

– Trucheck™ FemmeSafe (breast, ovary, uterus, cervix)

Trublood is a minimally invasive diagnostic test that can clearly identify cancer in symptomatic patients.
Trublood provides diagnostic information similar to that provided by tissue biopsy when it is not conclusive or not possible.
Based on the test results, therapy can be tailored.

exacta is a comprehensive analysis of the molecular-genetic characteristics of solid tumours, based on the results of several clinical studies. Especially for rare solid tumours for which no guidelines are available, in advanced disease or for difficult-to-treat tumours, Exacta is an advantage. Exacta analyses millions of data at the molecular level to identify all relevant targets for individualised therapy.

celldx

Deep genomic analysis of solid tumours

Celldx is a tissue-based comprehensive molecular profiling of solid tumours to tailor treatment options.
Results are usually available within eight working days and, in addition to genetic analysis, provide information on the usefulness of immune checkpoint inhibitors.

cancertrack

Blood-based follow-up for all solid organic tumours

Cancertrack is a blood-based assay that detects cancer-related biomarkers with extremely high accuracy, specificity and reliability.
Cancertrack enables continuous cancer monitoring to detect recurrences or changes in tumour characteristics at an early stage.

chemo-scale

Minimally invasive in-vitro chemotherapy susceptibility testing

Cancer is an extremely heterogeneous disease.
Chemotherapies do not work the same for every patient.
Chemo-scale uses a blood sample to study the effectiveness of chemotherapies in an individual patient.
The likelihood of successful therapy can be significantly increased in certain cases, while treatment failure can be largely prevented.

Crystal, medical centre, d.o.o.

naslov

Address

Štukljeva cesta 46, 1000 Ljubljana
crystal-phone

Reception

01 235 50 20
email01

E-mail

info@crystalmc.si
instagram-1

Follow us

on Instagram
facebook-1

Follow us

on Facebook

Book an appointment or ask a question

1 Step 1
keyboard_arrow_leftPrevious
Nextkeyboard_arrow_right
FormCraft - WordPress form builder